Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy

NCT02846792 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02846792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02846792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Terminated
Start date
June 14, 2017
Completion date
August 16, 2018
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene translocation, egfr activating mutation, recurrent non-small cell lung carcinoma, ros1 gene translocation, stage iiib non-small cell lung cancer ajcc v7, stage iv non-small cell lung cancer ajcc v7